These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 28427845)
1. Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout. Lee SS; Phy K; Peden K; Sheng-Fowler L Vaccine; 2017 Oct; 35(41):5481-5486. PubMed ID: 28427845 [TBL] [Abstract][Full Text] [Related]
2. High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test. Konduru K; Shurtleff AC; Bavari S; Kaplan G J Virol Methods; 2018 Apr; 254():1-7. PubMed ID: 29355585 [TBL] [Abstract][Full Text] [Related]
3. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. Morozov I; Monath TP; Meekins DA; Trujillo JD; Sunwoo SY; Urbaniak K; Kim IJ; Narayanan SK; Indran SV; Ma W; Wilson WC; O'Connor C; Dubey S; Troth SP; Coller BA; Nichols R; Martin BK; Feldmann H; Richt JA Emerg Microbes Infect; 2021 Dec; 10(1):651-663. PubMed ID: 33719915 [No Abstract] [Full Text] [Related]
4. Development of a vesicular stomatitis virus pseudotyped with herpes B virus glycoproteins and its application in a neutralizing antibody detection assay. Kinoshita H; Yamada S; Ogawa T; Nguyen PHA; Harada S; Kawahara M; Ishijima K; Maeda K; Ebihara H; Fukushi S mBio; 2024 Jul; 15(7):e0109224. PubMed ID: 38847539 [TBL] [Abstract][Full Text] [Related]
5. Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species. Bergren NA; Miller MR; Monath TP; Kading RC Hum Vaccin Immunother; 2018 Apr; 14(4):994-1002. PubMed ID: 29206076 [TBL] [Abstract][Full Text] [Related]
6. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors. Fang X; Zhang S; Sun X; Li J; Sun T Vaccine; 2012 Feb; 30(7):1313-21. PubMed ID: 22222871 [TBL] [Abstract][Full Text] [Related]
9. Characterization of Antibody Interactions with the G Protein of Vesicular Stomatitis Virus Indiana Strain and Other Vesiculovirus G Proteins. Munis AM; Tijani M; Hassall M; Mattiuzzo G; Collins MK; Takeuchi Y J Virol; 2018 Dec; 92(23):. PubMed ID: 30232190 [TBL] [Abstract][Full Text] [Related]
10. Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses. Bounds CE; Kwilas SA; Kuehne AI; Brannan JM; Bakken RR; Dye JM; Hooper JW; Dupuy LC; Ellefsen B; Hannaman D; Wu H; Jiao JA; Sullivan EJ; Schmaljohn CS PLoS One; 2015; 10(9):e0137786. PubMed ID: 26422247 [TBL] [Abstract][Full Text] [Related]
11. Recombinant adenovirus expressing vesicular stomatitis virus G proteins induce both humoral and cell-mediated immune responses in mice and goats. Xue X; Yu Z; Jin H; Liang L; Li J; Li X; Wang Y; Cui S; Li G BMC Vet Res; 2021 Jan; 17(1):36. PubMed ID: 33461549 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs. Locher S; Schweneker M; Hausmann J; Zimmer G J Gen Virol; 2018 Jul; 99(7):866-879. PubMed ID: 29869979 [TBL] [Abstract][Full Text] [Related]
14. Protective efficacy of a recombinant Newcastle disease virus expressing glycoprotein of vesicular stomatitis virus in mice. Zhang M; Ge J; Li X; Chen W; Wang X; Wen Z; Bu Z Virol J; 2016 Feb; 13():31. PubMed ID: 26911572 [TBL] [Abstract][Full Text] [Related]
15. Establishment of replication-competent vesicular stomatitis virus recapitulating SADS-CoV entry. Zhu Z; Han Y; Gong M; Sun B; Zhang R; Ding Q J Virol; 2024 May; 98(5):e0195723. PubMed ID: 38557247 [TBL] [Abstract][Full Text] [Related]
16. Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1. Ao Z; Wang L; Azizi H; Olukitibi TA; Kobinger G; Yao X J Virol; 2021 Jul; 95(15):e0236820. PubMed ID: 34011553 [TBL] [Abstract][Full Text] [Related]
17. Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein. Mahon BE; Simon J; Widdowson MA; Samai M; Rogier E; Legardy-Williams J; Liu K; Schiffer J; Lange J; DeByle C; Pinner R; Schuchat A; Slutsker L; Goldstein S J Infect Dis; 2021 Dec; 224(11):1907-1915. PubMed ID: 34013349 [TBL] [Abstract][Full Text] [Related]
18. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Wec AZ; Herbert AS; Murin CD; Nyakatura EK; Abelson DM; Fels JM; He S; James RM; de La Vega MA; Zhu W; Bakken RR; Goodwin E; Turner HL; Jangra RK; Zeitlin L; Qiu X; Lai JR; Walker LM; Ward AB; Dye JM; Chandran K; Bornholdt ZA Cell; 2017 May; 169(5):878-890.e15. PubMed ID: 28525755 [TBL] [Abstract][Full Text] [Related]
19. Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies. Ilinykh PA; Shen X; Flyak AI; Kuzmina N; Ksiazek TG; Crowe JE; Bukreyev A J Virol; 2016 Apr; 90(8):3890-3901. PubMed ID: 26819310 [TBL] [Abstract][Full Text] [Related]
20. A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses. Saito T; Maruyama J; Nagata N; Isono M; Okuya K; Takadate Y; Kida Y; Miyamoto H; Mori-Kajihara A; Hattori T; Furuyama W; Ogawa S; Iida S; Takada A Viruses; 2020 Aug; 12(9):. PubMed ID: 32842671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]